Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
184 shown of 7,135 total abstracts
  1. Abstract 19832026-06-03 · 16:15 CT · S100A
    PALOMA-456: Ibrance (palbociclib) maintenance in HR+ breast cancer
    J. Cortes, E. Winer, C. Robert, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 11442026-06-05 · 14:45 CT · S406
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    A. Spira, S. Modi · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract 14092026-06-04 · 19:15 CT · S406
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-672
    G. Curigliano, M. Reck, A. Spira, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract 14032026-06-02 · 18:45 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with TNBC
    F. Andre, T. Mok, C. Saura, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract 10182026-06-05 · 14:00 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-369
    S. Peters, N. Rizvi, C. Robert, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 14172026-06-04 · 18:00 CT · E450
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-577
    C. Robert, M. Reck · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 15822026-06-04 · 15:00 CT · S100A
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    E. Winer, T. Mok, L. Paz-Ares, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  8. Abstract 19152026-06-05 · 19:45 CT · S100A
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-722
    M.C. Garassino, J. Brahmer, E. Winer, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract 14322026-06-05 · 19:30 CT · Hall B1
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    L. Paz-Ares, M.C. Garassino, R. Herbst, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 13682026-06-02 · 15:15 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    T. Mok, S. Peters · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract 15152026-06-04 · 20:00 CT · S406
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    M.C. Garassino, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 14792026-06-04 · 18:30 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-664
    L. Paz-Ares, M. Reck, A. Spira · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract 16032026-06-01 · 14:45 CT · E450
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    S. Modi, A. Spira, C. Saura, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract 17242026-06-03 · 13:45 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-203 study)
    E. Winer, M. Krop, F. Andre, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 12192026-06-04 · 21:45 CT · S406
    MONALEESA-10: Kisqali (ribociclib) 2L in HR+ breast cancer
    M. Krop, G. Curigliano · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 18742026-06-05 · 19:15 CT · S100A
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    S. Modi, M.C. Garassino · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract 10312026-06-04 · 19:15 CT · Arie Crown Theater
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    R. Herbst, A. Spira, S. Tolaney, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 14282026-06-05 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-372 study)
    J. Brahmer, N. Rizvi, S. Modi · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract 10292026-06-05 · 18:30 CT · E450
    Long-term follow-up of Keytruda 3L+ for TNBC: KEYNOTE-141
    A. Spira, T. Mok, L. Paz-Ares, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  20. Abstract 17392026-06-04 · 13:30 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-907
    M. Krop, H. Rugo, E. Winer · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  21. Abstract 13172026-06-05 · 16:45 CT · E450
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-894
    M.C. Garassino, R. Herbst, T. Mok, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract 13672026-06-04 · 13:45 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-351
    M. Reck, E. Winer, A. Spira, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 16722026-06-04 · 18:15 CT · E450
    Long-term follow-up of Keytruda 1L for TNBC: KEYNOTE-438
    S. Peters, H. Borghaei, T. Mok, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract 11852026-06-03 · 15:30 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-926 study)
    M.C. Garassino, S. Tolaney · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract 10912026-06-01 · 19:15 CT · E450
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-484
    E. Winer, S. Tolaney, T. Mok · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 10522026-06-05 · 21:00 CT · S100A
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-395
    R. Herbst, G. Curigliano, J. Brahmer, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract 13722026-06-05 · 16:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-980 study)
    T. Mok, H. Rugo · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  28. Abstract 12992026-06-01 · 20:45 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-646
    S. Modi, M. Krop, M. Reck, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract 17252026-06-03 · 21:15 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-942
    A. Spira, C. Saura, S. Peters · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract 12012026-06-05 · 20:30 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-275
    E. Winer, M.C. Garassino, S. Antonia · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  31. Abstract 16572026-06-04 · 16:45 CT · S100A
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-150 study)
    C. Robert, G. Curigliano, L. Paz-Ares, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  32. Abstract 16852026-06-01 · 18:00 CT · E450
    Quality of life outcomes with Tecentriq in patients with TNBC
    M. Krop, H. Rugo, N. Rizvi, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  33. Abstract 17202026-06-01 · 14:30 CT · S100A
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-962
    S. Modi, J. Cortes · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract 11512026-06-03 · 15:45 CT · E450
    PALOMA-578: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    M. Reck, N. Rizvi · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 14402026-06-04 · 18:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-124 study)
    L. Paz-Ares, H. Rugo, S. Peters, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  36. Abstract 10542026-06-04 · 15:15 CT · Arie Crown Theater
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-341
    H. Borghaei, J. Cortes, G. Curigliano, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  37. Abstract 18472026-06-03 · 19:00 CT · S406
    Long-term follow-up of Keytruda 2L for TNBC: KEYNOTE-532
    S. Modi, G. Curigliano, F. Andre, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  38. Abstract 19612026-06-01 · 13:15 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-729
    A. Spira, M.C. Garassino, S. Tolaney · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract 16392026-06-02 · 21:45 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-288 study)
    S. Modi, J. Brahmer, S. Peters · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 12802026-06-05 · 21:45 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-853
    R. Herbst, P. Schmid, M. Reck · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  41. Abstract 15272026-06-02 · 18:30 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-384
    M. Reck, S. Modi, C. Saura, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  42. Abstract 17852026-06-04 · 21:30 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-418
    L. Paz-Ares, J. Brahmer, P. Schmid · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  43. Abstract 13762026-06-01 · 13:30 CT · S100A
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    F. Andre, J. Cortes · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  44. Abstract 13062026-06-04 · 15:15 CT · S100A
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    S. Modi, R. Herbst · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  45. Abstract 13702026-06-03 · 19:45 CT · S406
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-521
    S. Antonia, C. Robert, N. Rizvi · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  46. Abstract 16612026-06-04 · 15:45 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-267
    A. Spira, T. Mok, M. Reck · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  47. Abstract 18102026-06-01 · 18:15 CT · Hall B1
    Quality of life outcomes with Trodelvy in patients with TNBC
    E. Winer, S. Tolaney, L. Paz-Ares, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  48. Abstract 18902026-06-02 · 21:15 CT · S100A
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-338
    J. Brahmer, R. Herbst, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract 18912026-06-03 · 16:15 CT · S100A
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-490 study)
    N. Rizvi, A. Spira, S. Modi, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  50. Abstract 11542026-06-03 · 19:15 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-472
    N. Rizvi, J. Cortes, R. Herbst · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  51. Abstract 16732026-06-02 · 14:30 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-886
    F. Andre, M.C. Garassino, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  52. Abstract 14942026-06-03 · 13:00 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-858 study)
    S. Modi, H. Rugo · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  53. Abstract 17102026-06-04 · 13:00 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    E. Winer, M. Krop, S. Modi, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  54. Abstract 18532026-06-01 · 16:30 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-323
    S. Modi, H. Rugo · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  55. Abstract 13822026-06-01 · 20:30 CT · Hall B1
    DESTINY-Breast-284: Enhertu (trastuzumab deruxtecan) 3L+ in HR+ breast cancer
    N. Rizvi, T. Mok, G. Curigliano, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 15272026-06-02 · 16:15 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-341 study)
    S. Antonia, N. Rizvi, C. Saura · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  57. Abstract 14892026-06-02 · 13:30 CT · E450
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-621
    R. Herbst, G. Curigliano, S. Peters · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  58. Abstract 16532026-06-05 · 13:00 CT · E450
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-501 study)
    S. Peters, M. Reck, G. Curigliano, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract 16792026-06-01 · 14:00 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-632 study)
    M. Krop, L. Paz-Ares, C. Robert, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  60. Abstract 14432026-06-01 · 18:30 CT · S100A
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-199 study)
    H. Borghaei, S. Modi · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  61. Abstract 12492026-06-03 · 21:15 CT · Hall B1
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-35
    R. Herbst, S. Modi, S. Tolaney, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  62. Abstract 15552026-06-04 · 14:15 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-876
    R. Herbst, S. Peters, C. Saura, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  63. Abstract 15722026-06-01 · 13:15 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-774
    S. Peters, N. Rizvi · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  64. Abstract 15952026-06-04 · 13:00 CT · Arie Crown Theater
    IMpower-910: Tecentriq (atezolizumab) 1L in TNBC
    J. Brahmer, E. Winer, T. Mok · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  65. Abstract 11042026-06-02 · 19:00 CT · Hall B1
    DESTINY-Breast-639: Enhertu (trastuzumab deruxtecan) 3L+ in HR+ breast cancer
    P. Schmid, J. Brahmer · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  66. Abstract 15272026-06-02 · 20:30 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-53 study)
    S. Antonia, E. Winer, A. Spira, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  67. Abstract 11642026-06-04 · 20:45 CT · Arie Crown Theater
    PALOMA-161: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    G. Curigliano, L. Paz-Ares, F. Andre · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  68. Abstract 14972026-06-01 · 15:30 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-442 study)
    F. Andre, M. Krop, S. Peters · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  69. Abstract 14962026-06-05 · 15:15 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-121
    S. Antonia, J. Brahmer · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  70. Abstract 12682026-06-01 · 14:00 CT · E450
    MONARCH-173: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    N. Rizvi, S. Tolaney · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  71. Abstract 15662026-06-02 · 16:30 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-662
    H. Borghaei, R. Herbst, N. Rizvi · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  72. Abstract 13362026-06-02 · 16:45 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-311 study)
    S. Antonia, L. Paz-Ares, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  73. Abstract 10152026-06-03 · 16:15 CT · Hall B1
    MONARCH-98: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    M. Reck, S. Tolaney, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  74. Abstract 12362026-06-03 · 15:00 CT · Hall B1
    MONARCH-821: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    P. Schmid, G. Curigliano, R. Herbst, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  75. Abstract 14902026-06-01 · 13:45 CT · S100A
    PALOMA-184: Ibrance (palbociclib) maintenance in HR+ breast cancer
    J. Brahmer, E. Winer, C. Robert, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  76. Abstract 12202026-06-04 · 14:15 CT · E450
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-135
    S. Antonia, M.C. Garassino, E. Winer · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  77. Abstract 11592026-06-04 · 20:45 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-979
    E. Winer, M. Reck · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  78. Abstract 14782026-06-01 · 21:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-733 study)
    M. Reck, S. Modi, P. Schmid, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  79. Abstract 17432026-06-01 · 14:30 CT · E450
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-899
    L. Paz-Ares, S. Modi · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  80. Abstract 14352026-06-02 · 16:45 CT · E450
    MONARCH-359: Verzenio (abemaciclib) 2L in HR+ breast cancer
    H. Rugo, F. Andre, S. Tolaney · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  81. Abstract 18422026-06-05 · 15:45 CT · S100A
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-793
    J. Brahmer, L. Paz-Ares, M. Reck, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  82. Abstract 16462026-06-03 · 20:45 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-663 study)
    S. Peters, H. Rugo · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  83. Abstract 19832026-06-02 · 16:45 CT · S406
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-333
    C. Saura, R. Herbst, J. Brahmer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  84. Abstract 11482026-06-04 · 16:45 CT · E450
    Long-term follow-up of Lynparza 2L for HR+ breast cancer: OlympiA-922
    A. Spira, P. Schmid, C. Saura · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  85. Abstract 13542026-06-05 · 19:15 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-331
    M. Krop, H. Borghaei, J. Cortes, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  86. Abstract 14162026-06-01 · 19:30 CT · Hall B1
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-966
    M. Krop, H. Borghaei, A. Spira, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  87. Abstract 18732026-06-04 · 18:15 CT · S100A
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    A. Spira, S. Peters · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  88. Abstract 10752026-06-04 · 14:45 CT · Arie Crown Theater
    IMpower-457: Tecentriq (atezolizumab) 2L in TNBC
    T. Mok, N. Rizvi, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  89. Abstract 11542026-06-05 · 18:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-492 study)
    P. Schmid, S. Antonia, S. Tolaney, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  90. Abstract 12882026-06-05 · 20:00 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-209
    R. Herbst, G. Curigliano, S. Antonia, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  91. Abstract 14632026-06-04 · 16:30 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-616 study)
    E. Winer, G. Curigliano, M. Krop, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  92. Abstract 17892026-06-04 · 18:30 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-592
    C. Robert, C. Saura, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  93. Abstract 19142026-06-04 · 15:30 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-247
    S. Peters, F. Andre, N. Rizvi, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  94. Abstract 18802026-06-03 · 15:15 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-829
    G. Curigliano, J. Cortes · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  95. Abstract 14112026-06-01 · 16:30 CT · Hall B1
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-79
    J. Brahmer, T. Mok, L. Paz-Ares, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  96. Abstract 11322026-06-01 · 19:15 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-683
    C. Saura, L. Paz-Ares · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  97. Abstract 16002026-06-05 · 15:00 CT · E450
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    S. Tolaney, S. Antonia · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  98. Abstract 14242026-06-01 · 21:30 CT · E450
    PALOMA-41: Ibrance (palbociclib) 2L in HR+ breast cancer
    S. Tolaney, R. Herbst · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  99. Abstract 12592026-06-01 · 15:45 CT · S100A
    ASCENT-212: Trodelvy (sacituzumab govitecan) 1L in TNBC
    J. Cortes, M. Reck, J. Brahmer · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  100. Abstract 15582026-06-04 · 16:45 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-278 study)
    M. Reck, T. Mok, A. Spira · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  101. Abstract 16522026-06-03 · 21:15 CT · Arie Crown Theater
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-991
    N. Rizvi, R. Herbst · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  102. Abstract 14172026-06-02 · 15:15 CT · S100A
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-371
    J. Brahmer, S. Peters, N. Rizvi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  103. Abstract 16672026-06-01 · 21:30 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-108
    C. Saura, F. Andre, M. Reck, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  104. Abstract 19692026-06-03 · 16:00 CT · Hall B1
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-42
    S. Peters, G. Curigliano, H. Rugo, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  105. Abstract 19562026-06-05 · 21:15 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-950
    R. Herbst, C. Robert, S. Modi, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  106. Abstract 15622026-06-05 · 16:45 CT · Hall B1
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-796
    E. Winer, S. Peters, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  107. Abstract 12772026-06-02 · 16:00 CT · Hall B1
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-736
    S. Modi, C. Robert, S. Tolaney · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  108. Abstract 13072026-06-01 · 16:30 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-861 study)
    M. Reck, T. Mok, M. Krop · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  109. Abstract 13152026-06-01 · 16:00 CT · E450
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-798
    T. Mok, P. Schmid, A. Spira, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  110. Abstract 10972026-06-02 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-899 study)
    L. Paz-Ares, S. Modi · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  111. Abstract 13462026-06-04 · 14:30 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-670 study)
    S. Antonia, J. Brahmer, J. Cortes, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  112. Abstract 10192026-06-05 · 13:45 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-148 study)
    H. Borghaei, R. Herbst, J. Brahmer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  113. Abstract 16232026-06-03 · 14:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-603 study)
    J. Brahmer, C. Saura, M. Reck, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  114. Abstract 13752026-06-04 · 14:30 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-162 study)
    R. Herbst, S. Antonia, C. Robert, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  115. Abstract 11362026-06-01 · 18:45 CT · E450
    Long-term follow-up of Trodelvy 3L+ for TNBC: ASCENT-242
    A. Spira, G. Curigliano, J. Brahmer, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  116. Abstract 17952026-06-04 · 16:15 CT · E450
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-790
    C. Robert, S. Modi, A. Spira · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  117. Abstract 12302026-06-05 · 16:15 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-328
    P. Schmid, L. Paz-Ares, H. Borghaei, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  118. Abstract 18262026-06-03 · 13:45 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-31
    S. Tolaney, M. Krop, A. Spira, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  119. Abstract 16752026-06-03 · 16:15 CT · S406
    Long-term follow-up of Lynparza 3L+ for HR+ breast cancer: OlympiA-169
    C. Saura, T. Mok · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  120. Abstract 14402026-06-05 · 20:00 CT · Hall B1
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-615
    N. Rizvi, E. Winer, C. Robert, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  121. Abstract 10802026-06-05 · 13:00 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-667
    N. Rizvi, C. Robert, F. Andre, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  122. Abstract 14092026-06-03 · 19:45 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-303 study)
    M.C. Garassino, J. Brahmer, J. Cortes, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  123. Abstract 17892026-06-02 · 19:00 CT · S406
    MONALEESA-820: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    S. Modi, H. Borghaei · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  124. Abstract 16042026-06-05 · 20:30 CT · S406
    MONALEESA-930: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    L. Paz-Ares, J. Brahmer, F. Andre, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  125. Abstract 18502026-06-01 · 15:00 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-278
    G. Curigliano, F. Andre, J. Cortes, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  126. Abstract 15052026-06-04 · 15:30 CT · S406
    Long-term follow-up of Enhertu maintenance for HR+ breast cancer: DESTINY-Breast-316
    C. Robert, G. Curigliano · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  127. Abstract 13622026-06-05 · 15:00 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-770
    A. Spira, M. Reck, F. Andre, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  128. Abstract 16092026-06-01 · 16:15 CT · E450
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-336 study)
    M.C. Garassino, E. Winer, S. Antonia, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  129. Abstract 15822026-06-04 · 21:00 CT · S100A
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-961
    R. Herbst, S. Peters, H. Borghaei · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  130. Abstract 10162026-06-01 · 13:45 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-532 study)
    R. Herbst, C. Robert · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  131. Abstract 10552026-06-03 · 19:15 CT · Hall B1
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-850
    T. Mok, M. Reck, F. Andre · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  132. Abstract 17762026-06-05 · 18:30 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-838
    P. Schmid, J. Brahmer · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  133. Abstract 19332026-06-05 · 18:00 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-451 study)
    L. Paz-Ares, F. Andre, R. Herbst · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  134. Abstract 14822026-06-05 · 20:00 CT · Hall B1
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-57
    A. Spira, N. Rizvi, S. Peters, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  135. Abstract 19172026-06-05 · 15:15 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-461 study)
    M. Krop, J. Brahmer, C. Robert · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  136. Abstract 16862026-06-02 · 20:45 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-610
    R. Herbst, F. Andre, L. Paz-Ares, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  137. Abstract 18002026-06-01 · 15:00 CT · Arie Crown Theater
    DESTINY-Breast-200: Enhertu (trastuzumab deruxtecan) maintenance in HR+ breast cancer
    P. Schmid, S. Peters · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  138. Abstract 19062026-06-04 · 14:15 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-73
    M. Krop, A. Spira, H. Borghaei · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  139. Abstract 18712026-06-01 · 13:45 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-182
    M.C. Garassino, L. Paz-Ares · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  140. Abstract 19662026-06-01 · 13:15 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-285 study)
    F. Andre, H. Borghaei, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  141. Abstract 13692026-06-05 · 19:00 CT · Arie Crown Theater
    PALOMA-511: Ibrance (palbociclib) 2L in HR+ breast cancer
    C. Saura, A. Spira, S. Antonia, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  142. Abstract 17122026-06-04 · 20:45 CT · E450
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-468
    S. Peters, G. Curigliano, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  143. Abstract 18972026-06-02 · 15:30 CT · E450
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-97
    L. Paz-Ares, J. Brahmer, H. Borghaei, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  144. Abstract 13632026-06-01 · 19:00 CT · Arie Crown Theater
    PALOMA-544: Ibrance (palbociclib) 2L in HR+ breast cancer
    H. Rugo, E. Winer · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  145. Abstract 10152026-06-02 · 15:00 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-144 study)
    F. Andre, H. Rugo, C. Saura, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  146. Abstract 10652026-06-01 · 18:15 CT · S406
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-625
    L. Paz-Ares, A. Spira, M.C. Garassino, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  147. Abstract 10292026-06-01 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy 2L for TNBC: ASCENT-610
    A. Spira, G. Curigliano · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  148. Abstract 10282026-06-05 · 21:30 CT · Hall B1
    IMpower-697: Tecentriq (atezolizumab) neoadjuvant in TNBC
    N. Rizvi, L. Paz-Ares, C. Saura · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  149. Abstract 17232026-06-01 · 21:45 CT · S406
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-887
    F. Andre, J. Brahmer, M.C. Garassino, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  150. Abstract 15312026-06-02 · 20:30 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-981
    M. Reck, C. Saura · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  151. Abstract 16412026-06-04 · 19:30 CT · E450
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-504 study)
    T. Mok, J. Cortes · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  152. Abstract 17012026-06-05 · 18:45 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-655
    G. Curigliano, J. Brahmer, N. Rizvi · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  153. Abstract 18942026-06-02 · 14:00 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-974
    A. Spira, J. Brahmer · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  154. Abstract 11532026-06-05 · 18:00 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-329
    L. Paz-Ares, T. Mok, C. Saura, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  155. Abstract 18282026-06-03 · 13:00 CT · Arie Crown Theater
    MONALEESA-691: Kisqali (ribociclib) 1L in HR+ breast cancer
    E. Winer, C. Robert, L. Paz-Ares · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  156. Abstract 18172026-06-04 · 20:30 CT · Hall B1
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-420
    M.C. Garassino, R. Herbst, J. Cortes · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  157. Abstract 14982026-06-04 · 16:30 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-47
    N. Rizvi, A. Spira, C. Saura, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  158. Abstract 10402026-06-05 · 21:00 CT · Hall B1
    OlympiA-818: Lynparza (olaparib) 1L in HR+ breast cancer
    H. Borghaei, P. Schmid · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  159. Abstract 16192026-06-03 · 14:15 CT · S100A
    KEYNOTE-259: Keytruda (pembrolizumab) adjuvant in TNBC
    S. Antonia, M. Reck, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  160. Abstract 15442026-06-01 · 21:45 CT · S406
    Long-term follow-up of Enhertu maintenance for HR+ breast cancer: DESTINY-Breast-311
    H. Rugo, J. Brahmer, G. Curigliano · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  161. Abstract 10482026-06-01 · 14:45 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-647
    H. Rugo, J. Cortes, G. Curigliano · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  162. Abstract 10562026-06-02 · 21:30 CT · E450
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-212
    C. Robert, C. Saura · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  163. Abstract 19612026-06-05 · 15:45 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-34
    S. Modi, N. Rizvi, C. Saura, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  164. Abstract 12512026-06-05 · 14:30 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-458
    M. Reck, S. Tolaney, E. Winer, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  165. Abstract 18782026-06-02 · 14:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-386 study)
    J. Brahmer, M.C. Garassino, C. Saura, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  166. Abstract 12642026-06-04 · 21:15 CT · E450
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-153
    S. Tolaney, A. Spira · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  167. Abstract 14472026-06-04 · 19:15 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-462 study)
    M. Reck, R. Herbst, F. Andre, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  168. Abstract 15702026-06-04 · 18:45 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-358 study)
    G. Curigliano, M. Krop, R. Herbst, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  169. Abstract 11812026-06-04 · 20:30 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-414
    M. Krop, G. Curigliano, L. Paz-Ares, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  170. Abstract 18742026-06-03 · 16:30 CT · E450
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-676
    H. Rugo, L. Paz-Ares, G. Curigliano, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  171. Abstract 19862026-06-01 · 16:15 CT · E450
    PALOMA-131: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    L. Paz-Ares, E. Winer, M. Krop · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  172. Abstract 11012026-06-05 · 15:45 CT · E450
    MONARCH-193: Verzenio (abemaciclib) 1L in HR+ breast cancer
    A. Spira, J. Cortes, S. Peters · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  173. Abstract 19802026-06-04 · 21:30 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-372
    A. Spira, R. Herbst, S. Modi · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  174. Abstract 10462026-06-03 · 15:15 CT · E450
    Long-term follow-up of Tecentriq adjuvant for TNBC: IMpower-580
    M. Krop, G. Curigliano, N. Rizvi, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  175. Abstract 11652026-06-01 · 13:15 CT · S406
    PALOMA-337: Ibrance (palbociclib) maintenance in HR+ breast cancer
    C. Robert, R. Herbst, A. Spira · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  176. Abstract 10182026-06-03 · 20:30 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-273
    G. Curigliano, J. Brahmer, S. Antonia, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  177. Abstract 17632026-06-04 · 14:00 CT · S100A
    MONALEESA-326: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    J. Cortes, M. Krop · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  178. Abstract 17072026-06-01 · 21:00 CT · Arie Crown Theater
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-510
    M. Reck, S. Peters · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  179. Abstract 13472026-06-01 · 13:15 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-879
    C. Robert, R. Herbst, P. Schmid, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  180. Abstract 16522026-06-02 · 16:15 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-816
    J. Cortes, P. Schmid, M.C. Garassino · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  181. Abstract 14132026-06-05 · 14:45 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-393
    J. Brahmer, S. Peters, C. Saura, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  182. Abstract 11872026-06-01 · 19:00 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-141 study)
    R. Herbst, H. Rugo, H. Borghaei, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  183. Abstract 11362026-06-02 · 15:45 CT · S100A
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-464
    C. Robert, N. Rizvi · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  184. Abstract 19482026-06-05 · 15:30 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-740
    J. Brahmer, M.C. Garassino, H. Borghaei, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.